Annual Report

Overview

The report describes Windlas Biotech's FY25 growth, including revenue of ₹ 7,599 Million and expanded manufacturing capacity exceeding 8.5 Billion tablets and capsules annually. The company reports 1,346 personnel at March 31, 2025, alongside strengthened health, safety, and employee-development initiatives. Its CSR activity covered healthcare, education and skill development, animal welfare, and environmental sustainability, with total CSR spending of ₹ 11.13 million.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024-2025
Period: 1 April 2024 – 31 March 2025
Publication date: 22 May 2025
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services